Botulinum toxin for chronic rhinitis: A systematic review and meta ‐analysis

ConclusionsBTX-A improved TNSS and QOL in patients with chronic rhinitis. These effects were demonstrated up to 24  weeks post treatment. BTX-A was safe, well tolerated, and may be considered in patients who are refractory to current standard-of-care therapies.

Source: International Forum of Allergy and Rhinology - May 6, 2021 Category: Allergy & Immunology Authors: Kencho Rinzin, Minh P. Hoang, Kachorn Seresirikachorn, Kornkiat Snidvongs Tags: ORIGINAL ARTICLE Source Type: research